Natco Pharma settles dispute with Onyx Therapeutics
A settlement agreement has been signed between Natco Pharma and Onyx Therapeutics Inc. on patent litigation related to generic versions of 10mg, 30mg and 60mg of Kyprolis. Natco has partnered with Breckenridge Pharmaceutical, Inc., who will market the product in the United States.
The District court case has been dismissed and both the parties have reached an agreement on the issue. By virtue of the settlement, Natco and Breckenridge have been granted a license permitting the launch of their generic carfilzomib product in 2027 or sooner depending on certain occurrences.
Natco believes that its 10mg ANDA is sole first to file and could be eligible for 180-days marketing exclusivity for the 10mg strength under certain circumstances.
Kyprolis is a registered trademark of Onyx Therapeutics Inc. The prescription medication is used to treat relapsed or refractory multiple myeloma. The drug had sales of US$ 586 million for the year ending December 2018 in the United States.
On Thursday, the stock of Natco Pharma opened at Rs. 520 per share. During the day, it made an intra-day high and low of Rs. 522.90 and Rs. 510, respectively.